logo

Rigel Pharmaceuticals Inc. (RIGL)



Trade RIGL now with
  Date
  Headline
5/5/2021 4:06:14 PM Rigel Reports Q1 EPS Of $0.22 Vs. $0.13 Last Year
4/13/2021 7:02:23 AM Rigel Reports Positive Topline Results From Phase 2 Clinical Trial To Evaluate Safety Of Fostamatinib
4/7/2021 7:31:13 AM Rigel Announces Closing Of License Agreement With Lilly
3/11/2021 7:36:55 AM Rigel Completes Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In COVID-19 Patients
3/2/2021 4:02:42 PM Rigel Pharmaceuticals Q4 Loss/share $0.11 Vs. Loss $0.10 Year Ago
2/18/2021 6:34:55 AM Lilly, Rigel Announce Global License Agreement To Co-develop Rigel's R552 In All Indications
1/29/2021 2:51:24 PM Rigel Gets $16.5 Mln From U.S. Department Of Defense For Phase 3 Clinical Trial Of Fostamatinib In COVID-19 Patients
1/11/2021 7:34:10 AM Rigel Pharma Reports 2020 TAVALISSE Preliminary Net Product Sales Of About $61.7 Mln
11/17/2020 7:37:21 AM Rigel Pharma Reaches Agreement With FDA On Final Design Of FORWARD Study